Of relevance to this review, the IFN-α responsive genes in circulating leukocytes were measured as a surrogate of IFN-α production by TA-pDCs and were induced in all melanoma patients receiving i.t. SD-101 and pembrolizumab [248]. The gene discussed is IFNA1; the disease is melanoma.